Consilient Health will cease the distribution of the Theramex range of medicines in Ireland

Consilient Health wish to announce that as of the 1st of September, Consilient Health will no longer distribute the Theramex range of medicines in Ireland. From that date, Theramex will assume responsibility for the supply and distribution of these medicines. These medicines include Evorel 50mcg, Evorel Conti and Zoely. This transition should not impact continuity of supply. Please contact Consilient Health at irishoffice@consilienthealth.com if you have any queries up to the 31st of August 2025. From the 1st of September, all queries should be directed to Theramex at Tina.Backhouse@theramex.com, General Manager – UK & Ireland.

(IE-CH-1695) February 2025

Introducing Yanae®: A New Copper IUD

Consilient Health is excited to announce the upcoming launch of Yanae® in Ireland, a new copper intrauterine device (IUD) designed to prioritise patient comfort1,2. 

Yanae® is a non-hormonal copper IUD (Cu 380) coupled with the innovative CrossGlide™ inserter, which incorporates an inflatable membrane to ease the insertion process1,2.

  • Effective for up to 5 years as both regular and emergency contraception1
  • Constructed from high-purity copper (99.99%) and biocompatible materials, free from latex, phthalates, or animal-derived substances1
  • CE-marked as a Class III medical device, ensuring compliance with stringent safety and performance standards​1
  • Yanae® employs the use of an inflatable membrane which aids adaptation to the shape of the uterus, helping the device to glide through the cervix and into the uterine cavity without friction​2

Patient-Centric Design

Yanae® has been designed with patient comfort at its core. The innovative inflatable membrane technology may enhance patient satisfaction by providing a gentle insertion experience. This approach aims to address common barriers to IUD uptake, such as fear of pain or discomfort​2.

Availability and Pricing

Yanae® will be available in Ireland from the end of January. The device is included in the Free Contraceptive Scheme, GMS Number 67255

Training 

Consilient Health strongly encourage completion of inserter training before attempting an insertion. Healthcare professionals are invited to register for the Yanae® Launch Webinar at www.consilienthealth.ie/meetings. During this meeting, attendees can also express interest in upcoming in-person training events.

For more information, please contact Irishoffice@consilienthealth.com 

 

1 Yanae® IFU, 2024.

2 Canela, Desjardin. Yanae® pilot Proof of Concept Study: feasibility and qualitative assessment. YANAE-P21001.April 2021. Proprietary document CEMAG CARE

IE-YAN-4 Date of Preparation January 2024. 

Prescribing Information

Yanae® Cu 380, featuring the innovative CrossGlide inserter, is a non-hormonal intrauterine device (IUD) developed by Pregna International LTD (India) and represented in Europe by MT Promedt Consulting GmbH (Germany). This CE 2460-certified medical device provides women of reproductive age with highly effective contraception, offering nearly complete protection against pregnancy for up to 5 years.

As a Class III regulated medical device, Yanae® complies with stringent safety and efficacy standards, ensuring it meets the highest requirements for healthcare products. It is important for practitioners and patients to carefully review the instructions for use before placement.

Yanae® is a non-hormonal contraceptive device and does not provide protection against sexually transmitted infections (STIs).

OCON Therapeutics will cease the supply of Ballerine® in Ireland

We regret to inform you that OCON Therapeutics, manufacturer of the IUB Ballerine®, have ceased the supply of Ballerine® in Ireland as of the 31st of December 2024. This is an OCON business decision and does not impact supply of Ballerine® to other territories.

From the 31st of December, OCON will answer any queries from patients or HCPS (atsupport@oconmed.com).

If you have concerns or queries, please do not hesitate to contact Consilient Health Ireland at irishoffice@consilienthealth.com or drugsafety@consilienthealth.com or OCON at support@oconmed.com.

Job bag code: IE-CH-1534(1)
Date of Preparation: December 2024

Menopause Workplace Excellence Silver Accreditation

Following on from our recognition the previous month at the Menopause Workplace Excellence Awards, we are proud to share that we have received our Menopause Workplace Excellence Silver Accreditation 2024!

As a workplace dedicated to continuous employee support, we are delighted to be included among leading organisations fostering supportive environments for employees navigating menopause.

 

IE-CH-1662 November 2024

Recognition for Consilient Health Ireland at Menopause Workplace Excellence Awards 2024

Consilient Health Ireland is proud to be recognised as a leading employer in supporting menopausal and perimenopausal women. In partnership with The Menopause Hub Academy and Great Place to Work, the Menopause Workplace Excellence Awards honours organizations that are creating inclusive, supportive environments for employees experiencing menopause.

Our Menopause Policy is regularly updated and supported by a team of 10 Mental Health First Aiders (MHFAs), who are specially trained in menopause support. All managers receive annual training on both mental health and menopause, ensuring the policy remains a key component of our commitment to well-being and inclusion.

In addition, we promote Menopause in the Workplace Education through internal ‘lunch and learn’ sessions.

Our Menopause Policy is integral to our broader ongoing commitment to employee well-being and a supportive environment for all.

 

IE-CH-1637   Date of Preparation: October 20

Consilient Health are Great Place to Work® Ireland certified for two consecutive years

Consilient Health is delighted to share that we are Great Place to Work® Ireland certified for two consecutive years! Recognitions such as these underscore our ongoing commitment to providing a supportive work environment for all employees.

IE-CH-1652 October 2024

Consilient Health announce the re-launch of Mysimba

Consilient Health are pleased to announce the re-launch of Mysimba, a prescription medicine which can help your patients achieve their weight loss goals.

Mysimba  is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of;

  • ≥ 30 kg/m2 (obese), or
  • ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co- morbidities e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension. 

Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

Guidelines suggest the use of MYSIMBA in patients with overweight or obesity with emotional eating.1

Consider MYSIMBA for your patients with emotional eating as due to its mode of action in the brain it is designed to help to control hunger and cravings. 1, 2

Support tools including a Mode of Action Video, Patient Information Booklet, Physician Prescribing Checklist and Dose Card are available on Mysimba.ie.

Click here to view the Mysimba SPC on medicines.ie.

Consilient Health can be contacted at  irishoffice@consilienthealth.com or drugsafety@consilienthealth.com.

 

References:

  1. Chianelli et al, Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment, Journal of Endocrinological Investigation, 2023, www.medicines.ie.
  2. Acosta et al, Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic, Obesity (2021) 29, 662-671.

 

MYS-0364-001 10/24
IE-CH-1634
Date of Preparation: October 2024

 

Consilient Health Ireland Wins Guaranteed Irish Award for the Pharmaceutical and MedTech Sector

On Thursday the 21st of March 2024, Consilient Health Ireland won the Guaranteed Irish Business Awards in the Pharmaceutical and MedTech Category. For 50 years, the licensed Guaranteed Irish symbol is the national symbol of trust and provenance for business in Ireland. This award is for companies who demonstrate excellent and innovative examples of how they incorporate the Guaranteed Irish core principles of Jobs, Community and Provenance into their day-to-day business, in a sustainable fashion.

Deirdre Kelly, Country Manager, and Luke Crosbie, Chief Executive say:
“We are delighted to receive this award. It is a testament to the support that we offer our staff and other stakeholders, not least the great work our team of mental health first aiders do to support our health and well-being as well as supporting a positive working environment at Consilient Health.”

Consilient Health is a privately owned pharmaceutical company, headquartered in Dublin. The company’s vision is to create value for all their stakeholders by bringing licensed pharmaceutical products to market. Being a sustainable business underpins everything we do at Consilient Health.

The company focuses on people, being responsible and remaining a competitive business.

Consilient Health Ireland can be contacted by emailing irishoffice@consilienthealth.com

 

Job bag code IE-CH-1549
Date of Preparation: March 2024

Consilient Health Ireland Joins Guaranteed Irish

Consilient Health Ireland has been named a member of Guaranteed Irish. The official Guaranteed Irish licensed mark is awarded to businesses based in Ireland that support sustainable jobs and contribute to local communities.

Consilient Health is a privately owned pharmaceutical company, headquartered in Dublin. The company’s vision is to create value for all their stakeholders by bringing licensed pharmaceutical products to market. Being a sustainable business underpins everything we do at Consilient Health.

The company focuses on people, being responsible and remaining a competitive business.

Consilient Health Ireland can be contacted by emailing irishoffice@consilienthealth.com

IE-CH-1410 | Date of prep: October 2023